KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Capital Expenditures (2016 - 2025)

Boston Scientific (BSX) has disclosed Capital Expenditures for 17 consecutive years, with $351.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 26.71% to $351.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $876.0 million through Dec 2025, up 10.89% year-over-year, with the annual reading at $876.0 million for FY2025, 10.89% up from the prior year.
  • Capital Expenditures hit $351.0 million in Q4 2025 for Boston Scientific, up from $181.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $351.0 million in Q4 2025 to a low of $75.0 million in Q1 2021.
  • Historically, Capital Expenditures has averaged $176.0 million across 5 years, with a median of $168.0 million in 2024.
  • Biggest YoY gain for Capital Expenditures was 118.37% in 2021; the steepest drop was 25.0% in 2021.
  • Year by year, Capital Expenditures stood at $266.0 million in 2021, then decreased by 20.3% to $212.0 million in 2022, then rose by 25.94% to $267.0 million in 2023, then grew by 3.75% to $277.0 million in 2024, then increased by 26.71% to $351.0 million in 2025.
  • Business Quant data shows Capital Expenditures for BSX at $351.0 million in Q4 2025, $181.0 million in Q3 2025, and $157.0 million in Q2 2025.